University of Hertfordshire

From the same journal

By the same authors

Documents

  • bjc2016433

    Final published version, 454 KB, PDF document

Links

  • Anna Kazarian
  • Oleg Blyuss
  • Gergana Metodieva
  • Aleksandra Gentry-Maharaj
  • Andy Ryan
  • Elena M Kiseleva
  • Olga M Prytomanova
  • Ian J Jacobs
  • Martin Widschwendter
  • Usha Menon
  • John F Timms
View graph of relations
Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalBritish Journal of Cancer
Volume116
Issue4
DOIs
Publication statusPublished - 14 Feb 2017

Abstract

BACKGROUND: Breast cancer is a leading cause of morbidity and mortality worldwide. Although mammography screening is available, there is an ongoing interest in improved early detection and prognosis. Herein, we have analysed a combination of serological biomarkers in a case-control cohort of sera taken before diagnosis.

METHODS: This nested case-control study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) used serum samples from 239 women who subsequently developed breast cancer and 239 matched cancer-free controls. Sera were screened by ELISA for 9 candidate markers. Univariate and multivariate analyses were performed to examine associations with clinico-pathological features and between case controls in different time groups before diagnosis.

RESULTS: Significant associations with clinico-pathological features related to prognosis were found for several candidates (CA15-3, HSP90A and PAI-1). However, there were no consistent differences between cases and controls for any candidate in the lead up to diagnosis. Whilst combination models outperformed single markers, there was no increase in performance towards diagnosis.

CONCLUSIONS: This study using unique pre-diagnosis samples shows that CA15-3, HSP90A and PAI-1 have potential as early prognostic markers and warrant further investigation. However, none of the candidates or combinations would be useful for screening.

ID: 18771904